| Issue Date | Title | Author(s) |
| 2-Nov-2023 | Alrizomadlin (APG-115) Alone or Combined with Azacitidine (AZA) in Patients (pts) with Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML) or Relapsed or Progressive Higher-Risk Myelodysplastic Syndrome (HR-MDS): Phase 1b Trial Results | Qi, Junyuan; Wei, Xudong; Li, Qiubai; Chang, Chukang; Zhou, Fuling; Huang, Jianying; Zhang, Yu; Xu, Chongyuan; Tang, Xiaowen; Jiang, Qian; Li, Junmin; Qin, Qun; He, Qun; Gao, Sujun; Liu, Liping; Chen, Zi; Yu, Min; Wang, Jing; Men, Lichuang; Wang, Hengbang; Ahmad, Mohammad; Yang, Dajun; Zhai, Yifan; Wang, Jianxiang |
| May-2021 | Dose escalation and expansion (phase Ia/Ib) study of GLS-010, a recombinant fully human antiprogrammed death-1 monoclonal antibody for advanced solid tumors or lymphoma | Liu, Dan; Ma, Chunguang; Lu, Ping; Gong, Jifang; Ye, Dingwei; Wang, Siyang; Peng, Peijian; Bai, Yuxian; Song, Yuqin; Chen, Jianhua; Jiang, Ou; Zhang, Guojun; Ba, Yi; Chen, Li; Pan, Jianji; Li, Qi; Zhang, Liling; Gu, Shanzhi; Yin, Xianli; Cao, Bangwei; Han, Weiqing; Dong, Haiying; Guo, Jianming; Zhang, Huilai; Su, Hang; Jiang, Yongsheng; Ouyang, Weiwei; Ma, Lulin; Sun, Yan; Zhang, Feng; Lv, Jun; Guo, Yabing; Xu, Chongyuan; Qi, Junyuan; Wang, Li; Wang, Xiang; Liu, Zhen; Shen, Lin |
| 2014 | Genetic Features of Late Onset Primary Hemophagocytic Lymphohistiocytosis in Adolescence or Adulthood | Wang, Yini; Wang, Zhao; Zhang, Jia; Wei, Qing; Tang, Ran; Qi, Junyuan; Li, Lihong; Ye, Liping; Wang, Jijun; Ye, Ling |
| 20-May-2020 | Gls-010, a novel anti-PD-1 mAb in Chinese patients with relapsed or refractory classical Hodgkin lymphoma: Preliminary impressive result of a phase II clinical trial. | Song, Yuqin; Zhu, Jun; Lin, Ningjing; Zhang, Mingzhi; Bai, Hai; Liu, Hui; Cui, Jie; Ke, Xiaoyan; Zhang, Huilai; Liu, Lihong; Yan, Dongmei; Jiang, Yongsheng; Zang, Aimin; Qi, Junyuan; Wang, Li; Liu, Zhuogang; Xu, Bing; Zhang, Ying; Zhang, Zhihui; Meng, Haijin |
| Aug-2020 | GLS-010, a novel fully human anti-PD-1 mAb in patients with advanced tumor: Preliminary results of a Phase Ib clinical trial | Shen, Lin; Gong, Jifang; Song, Yuqin; Ye, Dingwei; Lu, Zhihao; Wang, Siyang; Peng, Peijian; Chen, Jianhua; Jiang, Ou; Zhang, Guojun; Bai, Yuxian; Pan, Jianji; Ma, Chunguang; Chen, Li; Ma, Yi; Li, Qi; Lu, Ping; Zhang, Lingli; Yin, Xianli; Gu, Shanzhi; Zhang, Huilai; Su, Hang; Jiang, Yongsheng; Cao, Bangwei; Han, Weiqing; Sun, Yan; Zhang, Feng; Ouyang, Weiwei; Dong, Haiying; Guo, Jianming; Guo, Yabing; Xu, Chongyuan; Qi, Junyuan; Wang, Li; Lv, Jun; Wang, Xiang; Chen, Chris; Li, Jing; Zheng, Yong; Jin, Ge; Yang, Yining; Zhao, Guodong; Yang, Fan; Xu, Kehui; Liang, Xiangying; Pan, Zhaoyang; Meng, Haijin |
| 15-Jul-2020 | Pharmacokinetics and safety of IBI301 versus rituximab in patients with CD20(+) B-cell lymphoma: a multicenter, randomized, double-blind, parallel-controlled study | Jiang, Bo; Ke, Xiaoyan; Zhang, Qingyuan; Xu, Wei; Su, Hang; Huang, Jie; Zhang, Mingzhi; Wang, Huaqing; Jin, Chuan; Zhu, Jun; Liu, Li; Cai, Zhen; Zhao, Xielan; Zhou, Jianfeng; Zhang, Xiaohong; Liu, Jing; Zhou, Hui; Yu, Jie; Sun, Xing; Qi, Junyuan; Qiu, Lugui |
| 23-Aug-2021 | Phase 1 clinical trial of the PI3K delta inhibitor YY-20394 in patients with B-cell hematological malignancies | Jiang, Bo; Qi, Junyuan; Song, Yuqin; Li, Zengjun; Tu, Meifeng; Ping, Lingyan; Liu, Zongliang; Bao, Hanying; Xu, Zusheng; Qiu, Lugui |
| 2019 | A phase I study of a selective PI3K delta inhibitor YY-20394 in patients with relapsed or refractory B-cell malignancies. | Qiu, Lugui; Qi, Junyuan; Song, Yuqin; Jiang, Bo; Tu, Meifeng; Ping, Lingyan; Li, Zengjun; Zhu, Jun; Xu, Yuanyuan; Bao, Hanying; Xu, Zusheng |
| Jul-2024 | Phase I study of the Syk inhibitor sovleplenib in relapsed or refractory mature B-cell tumors | Song, Yuqin; Cao, Junning; Zhang, Qingyuan; Li, Caixia; Qiu, Lugui; Qi, Junyuan; Zhang, Huilai; Li, Wenyu; Liu, Lihong; Jing, Hongmei; Zhou, Keshu; Zhang, Weijing; Zhang, Liling; Li, Daqi; Zou, Liqun; Yang, Haiyan; Qian, Wenbin; Zhou, Hui; Hu, Jianda; Yin, Hongyan; Fu, Sisi; Fan, Songhua; Xu, Qian; Wang, Jian; Jia, Xiaoyun; Dai, Guangxiu; Su, Weiguo; Zhu, Jun |
| 2018 | Preliminary Results from a Phase 1 Study of HMPL-523, a Highly Selective Syk Inhibitor, in Chinese Patients with Mature B-Cell Lymphomas | Zhu, Jun; Cao, Junning; Qiu, Lugui; Qi, Junyuan; Song, Yuqin; Tu, Meifeng; Ji, Dongmei; Shen, Weina; Sun, Mingyuan; Hua, Ye; Yang, Chen; Yu, Chen; Wang, Jian; Dai, Guangxiu; Su, Weiguo |
| 2018 | Preliminary Results from a Phase I, First-in-Human Study of YY-20394, a Highly Selective and Highly Potent PI3K delta Inhibitor, in Patients with Relapsed or Refractory B-Cell Malignancies | Qi, Junyuan; Song, Yuqin; Jiang, Bo; Li, Jianyong; Tu, Meifeng; Ping, Lingyan; Li, Zengjun; Xu, Wei; Zhu, Huayuan; Zhu, Jun; Bao, Hanying; Xu, Zusheng; Qiu, Lugui |
| 15-Nov-2022 | Preliminary Safety and Efficacy Evaluation of IMM0306, a CD47 and CD20 Bispecific Monoclonal Antibody-Trap (mAbTrap), from an Ongoing Phase I Dose-Escalation Study in Patients with Relapsed or Refractory B-Cell Non- Hodgkin's Lymphoma (R/R B-NHL) | Shi, Yuankai; Song, Yongping; Zhang, Mingzhi; Jing, Hongmei; Wang, Zhen; Li, Zhiming; Qi, Junyuan; Li, Fei; Li, Wenyu; Yang, Jianliang; Gao, Siman; Ma, Huizi; He, Heming; Lu, Qiying; Tian, Wenzhi |
| Apr-2022 | A two-part, single-arm, multicentre, phase I study of zanubrutinib, a selective Bruton tyrosine kinase inhibitor, in Chinese patients with relapsed/refractory B-cell malignancies | Song, Yuqin; Sun, Mingyuan; Qi, Junyuan; Xu, Wei; Zhou, Jianfeng; Li, Dengju; Li, Jianyong; Qiu, Lugui; Du, Chenmu; Guo, Haiyi; Huang, Jane; Tang, Zhiyu; Ou, Ying; Wu, Binghao; Yu, Yiling; Zhu, Jun |
